Insights into Metabolism, Diagnostics and Therapeutics of Cancer and Tumor Microenvironment by NMR Spectroscopy

A special issue of Metabolites (ISSN 2218-1989). This special issue belongs to the section "Integrative Metabolomics".

Deadline for manuscript submissions: 30 September 2025 | Viewed by 3928

Special Issue Editors


E-Mail Website
Guest Editor
Department of Cancer Systems Imaging, University of Texas MD Anderson Cancer Center, 1881 East Road, Houston, TX, USA
Interests: metabolomics; NMR spectroscopy; MRI; hyperpolarized MRI; MRI contrast agents; cancer diagnosis; metabolic imaging; molecular imaging; cancer metabolism; PET; CT; dynamic nuclear polarization
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Department of Cancer Systems Imaging, University of Texas MD Anderson Cancer Center, Houston, TX, USA
Interests: metabolomics; NMR spectroscopy; MRI; hyperpolarized MRI; MRI contrast agents; cancer diagnosis; metabolic imaging; molecular imaging; cancer metabolism; PET; CT; dynamic nuclear polarization
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Cancer is driven largely by an altered metabolism to survive, proliferate, and metastasize. Altered metabolism is one of the hallmarks of cancer and has been an active area to explore for early diagnosis biomarkers and treatment targets. Understanding the role of metabolism in cancer and the related tumor microenvironment is crucial for controlling the disease and developing next-generation diagnostic biomarkers and therapeutic agents. Therefore, the timing is right to showcase the discoveries made and highlight the ongoing and upcoming research related to NMR-based cancer metabolomics in a single Special Issue of the journal Metabolites. This Special Issue has been designed to bring together original research articles, review articles, and communications related to cancer metabolism interrogated by NMR spectroscopy. The Special Issue will invite articles both on the recent technical developments of NMR spectroscopy, such as pulse sequence design, instrumentation, electronics and software to improve the sensitivity, specificity, resolution, data acquisition, quantification and analysis applicable to cancer metabolomics and metabolic imaging, as well as the applications of NMR spectroscopy in identifying biomarkers for the diagnosis, therapeutic intervention of cancer, and discovering metabolic targets for cancer therapy.

Dr. Shivanand M. Pudakalakatti
Dr. Pratip K. Bhattacharya
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Metabolites is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • cancer metabolism
  • early diagnosis
  • therapeutic intervention
  • NMR spectroscopy
  • instrument development
  • pulse sequence design
  • metabolites
  • software for metabolomics

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

16 pages, 2285 KiB  
Article
Hyperpolarized Magnetic Resonance Imaging, Nuclear Magnetic Resonance Metabolomics, and Artificial Intelligence to Interrogate the Metabolic Evolution of Glioblastoma
by Kang Lin Hsieh, Qing Chen, Travis C. Salzillo, Jian Zhang, Xiaoqian Jiang, Pratip K. Bhattacharya and Shyan Shams
Metabolites 2024, 14(8), 448; https://doi.org/10.3390/metabo14080448 - 14 Aug 2024
Viewed by 1190
Abstract
Glioblastoma (GBM) is a malignant Grade VI cancer type with a median survival duration of only 8–16 months. Earlier detection of GBM could enable more effective treatment. Hyperpolarized magnetic resonance spectroscopy (HPMRS) could detect GBM earlier than conventional anatomical MRI in glioblastoma murine [...] Read more.
Glioblastoma (GBM) is a malignant Grade VI cancer type with a median survival duration of only 8–16 months. Earlier detection of GBM could enable more effective treatment. Hyperpolarized magnetic resonance spectroscopy (HPMRS) could detect GBM earlier than conventional anatomical MRI in glioblastoma murine models. We further investigated whether artificial intelligence (A.I.) could detect GBM earlier than HPMRS. We developed a deep learning model that combines multiple modalities of cancer data to predict tumor progression, assess treatment effects, and to reconstruct in vivo metabolomic information from ex vivo data. Our model can detect GBM progression two weeks earlier than conventional MRIs and a week earlier than HPMRS alone. Our model accurately predicted in vivo biomarkers from HPMRS, and the results inferred biological relevance. Additionally, the model showed potential for examining treatment effects. Our model successfully detected tumor progression two weeks earlier than conventional MRIs and accurately predicted in vivo biomarkers using ex vivo information such as conventional MRIs, HPMRS, and tumor size data. The accuracy of these predictions is consistent with biological relevance. Full article
Show Figures

Figure 1

26 pages, 6753 KiB  
Article
Metabolite Biomarkers of Prolonged and Intensified Pain and Distress in Head and Neck Cancer Patients Undergoing Radio- or Chemoradiotherapy by Means of NMR-Based Metabolomics—A Preliminary Study
by Łukasz Boguszewicz, Alicja Heyda, Mateusz Ciszek, Agata Bieleń, Agnieszka Skorupa, Jolanta Mrochem-Kwarciak, Krzysztof Składowski and Maria Sokół
Metabolites 2024, 14(1), 60; https://doi.org/10.3390/metabo14010060 - 17 Jan 2024
Viewed by 2180
Abstract
Treatment of head and neck squamous cell carcinoma (HNSCC) has a detrimental impact on patient quality of life. The rate of recognized distress/depression among HNSCC patients ranges from 9.8% to 83.8%, and the estimated prevalence of depression among patients receiving radiotherapy is 63%. [...] Read more.
Treatment of head and neck squamous cell carcinoma (HNSCC) has a detrimental impact on patient quality of life. The rate of recognized distress/depression among HNSCC patients ranges from 9.8% to 83.8%, and the estimated prevalence of depression among patients receiving radiotherapy is 63%. Shorter overall survival also occurs in preexisting depression or depressive conditions. The present study analyzes the nuclear magnetic resonance (NMR) blood serum metabolic profiles during radio-/chemoradiotherapy and correlates the detected alterations with pain and/or distress accumulated with the disease and its treatment. NMR spectra were acquired on a Bruker 400 MHz spectrometer and analyzed using multivariate methods. The results indicate that distress and/or pain primarily affect the serum lipids and metabolites of energy (glutamine, glucose, lactate, acetate) and one-carbon (glycine, choline, betaine, methanol, threonine, serine, histidine, formate) metabolism. Sparse disturbances in the branched-chain amino acids (BCAA) and in the metabolites involved in protein metabolism (lysine, tyrosine, phenylalanine) are also observed. Depending on the treatment modality—radiotherapy or concurrent chemoradiotherapy—there are some differences in the altered metabolites. Full article
Show Figures

Figure 1

Back to TopTop